RUSC2 Inhibitors
RUSC2 inhibitors are a category of chemical compounds designed to target and modulate the activity of RUSC2, a protein encoded by the RUN and SH3 domain-containing 2 gene. These inhibitors are a subject of interest in the field of molecular biology and pharmacology due to the critical roles that RUSC2 plays in various cellular processes. RUSC2, also known as IPCEF1 (Interactor Protein for Cytohesin Exchange Factors 1), is a multi-functional protein involved in intracellular signaling and trafficking events. Its primary function revolves around regulating the dynamics of membrane-associated processes, such as endocytosis and vesicle transport, which are pivotal for cellular homeostasis.
RUSC2 inhibitors typically act by interfering with the binding of RUSC2 to its interaction partners or by modulating its enzymatic activity, depending on the specific mechanism of action. These inhibitors can serve as valuable tools in research to better understand the intricate roles of RUSC2 in cellular functions. They are also explored for regulating cellular processes that rely on RUSC2 activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). It competitively binds to the ATP-binding site of EGFR, preventing autophosphorylation and downstream signaling, thereby inhibiting cell proliferation and survival. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits multiple kinases, including Raf kinases, VEGFR, and PDGFR. By blocking these kinases, it disrupts cell signaling pathways involved in tumor growth and angiogenesis. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that primarily targets BCR-ABL, PDGFR, and c-KIT. It inhibits these kinases by binding to their ATP-binding sites, blocking their signaling and inhibiting cancer cell proliferation. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib targets multiple receptor tyrosine kinases, including VEGFR and PDGFR. It inhibits angiogenesis and tumor growth by interfering with these kinases' signaling pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual kinase inhibitor of EGFR and HER2. It blocks their ATP-binding sites, inhibiting phosphorylation and downstream signaling, thereby impeding cell growth and division. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Nilotinib, like Imatinib, targets BCR-ABL, but with higher selectivity. It binds to the ATP-binding site of BCR-ABL, preventing its activation and the proliferation of leukemia cells. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Pazopanib is a multi-kinase inhibitor targeting VEGFR, PDGFR, and c-KIT. It inhibits angiogenesis and tumor growth by blocking these kinases' activity. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib is a kinase inhibitor that targets various kinases involved in tumor growth and angiogenesis, including VEGFR and TIE2. It disrupts these pathways, hindering cancer progression. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib is a tyrosine kinase inhibitor that targets VEGFR and EGFR. By binding to their ATP-binding sites, it suppresses angiogenesis and tumor cell proliferation. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $92.00 $204.00 | 1 | |
XL-184 inhibits multiple kinases, including VEGFR, MET, and RET. It disrupts angiogenesis and tumor growth by interfering with these signaling pathways. | ||||||